- Previous Close
131.75 - Open
133.80 - Bid 128.00 x --
- Ask 128.85 x --
- Day's Range
127.90 - 133.80 - 52 Week Range
80.40 - 169.00 - Volume
14,925 - Avg. Volume
22,804 - Market Cap (intraday)
28.023B - Beta (5Y Monthly) 1.62
- PE Ratio (TTM)
-- - EPS (TTM)
-6.69 - Earnings Date Jan 28, 2025 - Feb 1, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Feb 14, 2019
- 1y Target Est
--
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities in central nervous system diseases. Its product candidates include Masupirdine (SUVN-502) for the treatment of Alzheimer disease and neuropsychiatric symptoms; Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist for the treatment of sleep and cognitive disorders; and Ropanicant (SUVN-911), Alpha4Beta2 nAChRs receptor antagonist for the treatment of depressive disorders. The company is developing Usmarapride (SUVN-D4010), a potent, selective, and orally bio-available and brain penetrant 5-HT4 receptor partial agonist for the treatment of cognitive disorders; SUVN-I6107 for the treatment of cognitive disorders; SUVN-M8036 for the treatment of psychiatric disorders; and SUVN-D1044 for the treatment of gastrointestinal disorders. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was incorporated in 1989 and is headquartered in Hyderabad, India. Suven Life Sciences Limited is a subsidiary of Jasti Property and Equity Holdings Private Limited.
www.suven.com141
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: SUVEN.BO
View MorePerformance Overview: SUVEN.BO
Trailing total returns as of 12/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SUVEN.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SUVEN.BO
View MoreValuation Measures
Market Cap
28.02B
Enterprise Value
26.34B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
333.49
Price/Book (mrq)
14.54
Enterprise Value/Revenue
312.97
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-36.70%
Return on Equity (ttm)
-54.98%
Revenue (ttm)
84.15M
Net Income Avi to Common (ttm)
-1.46B
Diluted EPS (ttm)
-6.69
Balance Sheet and Cash Flow
Total Cash (mrq)
1.66B
Total Debt/Equity (mrq)
0.13%
Levered Free Cash Flow (ttm)
-799.51M